Home Cart Sign in  
Chemical Structure| 717824-30-1 Chemical Structure| 717824-30-1

Structure of Vidofludimus
CAS No.: 717824-30-1

Chemical Structure| 717824-30-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vidofludimus is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 134 nM for human DHODH, used as a immunosuppressive drug.

Synonyms: 4sc-101; SC12267

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vidofludimus

CAS No. :717824-30-1
Formula : C20H18FNO4
M.W : 355.36
SMILES Code : O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O
Synonyms :
4sc-101; SC12267
MDL No. :MFCD18633262
InChI Key :XPRDUGXOWVXZLL-UHFFFAOYSA-N
Pubchem ID :9820008

Safety of Vidofludimus

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

    Human DHODH, IC50:134 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 0.4±0.2 μM 16 hours Evaluate the activation effect of Vidofludimus on Nurr1, showing significant agonist activity J Med Chem. 2023 May 11;66(9):6391-6402.
HEK293T cells 10 μmol/L 72 hours Evaluate the inhibitory effect of Vidofludimus on HEV replication, results showed significant inhibition of HEV replication Virol Sin. 2024 Feb;39(1):123-133.
HuH7 cells 10 μmol/L 72 hours Evaluate the inhibitory effect of Vidofludimus on HEV replication, results showed significant inhibition of HEV replication Virol Sin. 2024 Feb;39(1):123-133.
Huh-7 cells 20 μM 48 hours To evaluate the antiviral activity of Vidofludimus against SLEV in Huh-7 cells. Results showed no significant antiviral activity at 20 μM. Louis Encephalitis Virus. Viruses.
HBEC-5i cells 20 μM 48 hours To evaluate the antiviral activity of Vidofludimus against SLEV in HBEC-5i cells. Results showed no significant antiviral activity at 20 μM. Louis Encephalitis Virus. Viruses.
Vero CCL81 cells 20 μM 72 hours To evaluate the inhibitory effect of Vidofludimus on SLEV-induced cytopathic effects. Results showed that Vidofludimus inhibited SLEV-induced cytopathic effects at 20 μM. Louis Encephalitis Virus. Viruses.
Porcine alveolar macrophages (PAMs) 1-10 μM 48 hours Assess the anti-PRRSV activity of Vidofludimus in PAMs, showing significant dose-dependent inhibition Vet Res. 2023 Dec 20;54(1):124.
Marc-145 cells 1-10 μM 48 hours Evaluate the inhibitory effect of Vidofludimus on PRRSV replication, showing dose-dependent antiviral activity Vet Res. 2023 Dec 20;54(1):124.
MEF cells 5 µM 1 hour To investigate the FXR-dependent inhibitory effect of Vidofludimus on TNFα-induced IκBα degradation and nuclear p65 levels. Results showed that Vidofludimus significantly stabilized IκBα and inhibited nuclear p65 levels in WT MEFs, while these effects were substantially reduced in FXR KO MEFs. Front Pharmacol. 2020 May 14;11:590.
HepG2 cells 5 µM 1 hour To investigate the inhibitory effect of Vidofludimus on TNFα-induced IKKα/β phosphorylation and IκBα degradation. Results showed that Vidofludimus suppressed TNFα-induced phosphorylation of IKKα/β in a concentration-dependent manner, thereby inhibiting the degradation of IκBα protein. Front Pharmacol. 2020 May 14;11:590.
PBMCs 2.1 µM 7 days Evaluate the antiviral activity of Vidofludimus against HIV-1, showing effective inhibition of viral replication Viruses. 2020 Dec 5;12(12):1394.
Huh7 cells 5.9 µM 24 hours Assess the antiviral activity of Vidofludimus against HCV, showing effective inhibition of viral replication Viruses. 2020 Dec 5;12(12):1394.
HFF cells 7.4 µM 7 days Evaluate the antiviral activity of Vidofludimus against HCMV, showing effective inhibition of viral replication without detectable cytotoxicity Viruses. 2020 Dec 5;12(12):1394.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female Sprague Dawley rats Oral 5 mg/kg Single dose, observed for 8 hours Evaluate the pharmacokinetic properties of Vidofludimus, showing good bioavailability and plasma concentration J Med Chem. 2023 May 11;66(9):6391-6402.
Mice DSS-induced colitis model Oral 20 mg/kg/day Once daily until the end of the experiments To investigate the therapeutic effects of Vidofludimus on DSS-induced colitis and its FXR-dependency. Results showed that Vidofludimus significantly ameliorated DSS-induced colitis as assessed by reduced body weight loss, prevented colonic shortening, and decreased histological scores in WT mice, while these effects were not observed in FXR KO mice. Front Pharmacol. 2020 May 14;11:590.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.07mL

2.81mL

1.41mL

28.14mL

5.63mL

2.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories